<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080310</url>
  </required_header>
  <id_info>
    <org_study_id>YMC033</org_study_id>
    <nct_id>NCT04080310</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin</brief_title>
  <official_title>Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin: Study Protocol for a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, open-label, parallel, phase IV trial.&#xD;
&#xD;
      The purpose of this study efficacy and safety of combination therapy of moderate-intensity&#xD;
      statin and ezetimibe compared to high-intensity statin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned to include 272 patients with a clinical atherosclerotic cardiovascular&#xD;
      disease requiring optimal statin therapy.&#xD;
&#xD;
      After enrollment, subjects are randomized into two groups in a 1:1 manner. The combination&#xD;
      therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10&#xD;
      mg once daily.&#xD;
&#xD;
      The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.&#xD;
&#xD;
      Subjects will visit at weeks 12 and 24 to identify medication adherence and clinical side&#xD;
      effects.&#xD;
&#xD;
      The primary endpoint of this study is a % change of low-density lipoprotein cholesterol at 12&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% change of low-density lipoprotein cholesterol</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>%change of LDL-C = (LDL-C at 12 weeks) - (LDL-C at baseline)/LDL-C at baseline * 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% change of serum cholesterol level</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>total cholesterol, LDL, HDL cholesterol, triglyceride (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change of high-sensitivity C-reactive protein</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>hs-CRP(mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change of fasting glucose</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>fasting plasma glucose(mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change of homeostatic model assessment for insulin resistance(HOMA-IR)</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>HOMA-IR = glucose * insulin / 405(glucose mg/dL , insulin uIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participant with statin-associated muscle symptoms</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>occurrence of statin-associated muscle symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participant with creatinine phosphokinase elevation</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>proportion of CPK elevation ≥4 or ≥10 upper normal of limit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participant with liver function test abnormality</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>proportion of AST/ALT elevation ≥4 or ≥10 upper normal of limit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participant with major adverse cardiovascular and cerebrovascular events(MACCE)</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>MACCE defined as a composite of the followings : cardiovascular death, acute myocardial infarction, unstable angina, stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>combination therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The combination therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive statin group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin</intervention_name>
    <description>This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.&#xD;
After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily.</description>
    <arm_group_label>combination therapy group</arm_group_label>
    <arm_group_label>intensive statin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 19 and 75 years&#xD;
&#xD;
          2. Presence of atherosclerotic cardiovascular disease Coronary artery disease&#xD;
&#xD;
               -  History of acute coronary syndrome&#xD;
&#xD;
               -  Stable or unstable angina&#xD;
&#xD;
               -  History of coronary revascularization Stroke or TIA Peripheral arterial disease,&#xD;
                  history of peripheral arterial revascularization&#xD;
&#xD;
          3. Patients who have been taking lipid-lowering agents (statin or ezetimibe) for ≥4 weeks&#xD;
             at the time of randomization&#xD;
&#xD;
          4. Patients who gave informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have used lipid-lowering agents other than statin or ezetimibe within the&#xD;
             last 3 months&#xD;
&#xD;
          2. A serum triglyceride on fasting &gt;400 mg/dL&#xD;
&#xD;
          3. A history of muscular symptoms or rhabdomyolysis due to the use of statin&#xD;
&#xD;
          4. Hypersensitivity to rosuvastatin or ezetimibe&#xD;
&#xD;
          5. Labeled contraindications to rosuvastatin or rosuvastatin Severe renal impairment&#xD;
             (CrCl &lt;30 mL/min by Cockcroft-Gault formula or estimated GFR &lt;30 mL/min / 1.73 m2 by&#xD;
             MDRD equation) ALT, AST ≥3 × ULN or active liver disease CPK ≥3 × ULN&#xD;
&#xD;
          6. Enrollment of other clinical trials within 30 days&#xD;
&#xD;
          7. Any other issues that the treating physician assumes ineligible for participation in&#xD;
             the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>06511</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Si-Hyuck Kang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

